Intended for healthcare professionals


Multiple sclerosis: NICE recommends treatment for secondary progressive MS

BMJ 2020; 371 doi: (Published 15 October 2020) Cite this as: BMJ 2020;371:m3990
  1. Jacqui Wise
  1. London

The National Institute for Health and Care Excellence has recommended an oral drug for treating secondary progressive multiple sclerosis, the first new treatment for this group of patients in more than a decade.

The draft guidance recommends siponimod (marketed in the UK by Novartis as Mayzent) for patients with secondary progressive MS with evidence of active disease: those who have relapses or have evidence of inflammatory …

View Full Text

Log in

Log in through your institution


* For online subscription